Search research articles
Contact Us
Filters
Showing results (81-90 of 84) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 84 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 30, 2025
Preoperative Body Composition Parameters Are Associated With Postoperative Outcomes in Patients With Crohn's Disease
Michiel T J Bak, Karlijn Demers, Oddeke van Ruler, et al.
Journal of Crohn'S & Colitis
|
June 13, 2023
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
Fenna M Jansen, Reinier C A van Linschoten, Wietske Kievit, et al.
Digestive Diseases and Sciences
|
April 9, 2024
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The Lancet. Gastroenterology & Hepatology
|
February 3, 2023
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 84) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 84 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 30, 2025
Preoperative Body Composition Parameters Are Associated With Postoperative Outcomes in Patients With Crohn's Disease
Michiel T J Bak, Karlijn Demers, Oddeke van Ruler, et al.
Journal of Crohn'S & Colitis
|
June 13, 2023
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
Fenna M Jansen, Reinier C A van Linschoten, Wietske Kievit, et al.
Digestive Diseases and Sciences
|
April 9, 2024
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The Lancet. Gastroenterology & Hepatology
|
February 3, 2023
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
Page
of 9